Pembrolizumab Plus Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
Ovarian Cancer
Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Carboplatin Desensitization Associated With Improved Overall Survival in Recurrent Ovarian Cancer
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in BRCA-Mutant Ovarian Cancer
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
The Relationship Between Niraparib Dose Reduction and Efficacy in Ovarian Cancer
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.
Experience for Women With Ovarian Cancer After Multiple Lines of PARP Inhibitor Therapy
More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.
Simultaneous Sequencing of Paired Germline and Somatic Specimens Enhanced Clinical Care in Ovarian Cancer
Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.
ARIEL3: Rucaparib Maintenance Across Age Groups in Advanced Ovarian Cancer
Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.
Lymphadenectomy Found Not Beneficial in Advanced Ovarian Cancer
According to researchers, the Lymphadenectomy in Ovarian Neoplasms (LION) trial was meticulously designed to eliminate many potential confounding factors.
Next post in Gynecologic Cancer
